

(Incorporated in Bermuda with limited liability) (於百慕達註冊成立之有限公司) (Stock code 股份代號: 2552)

NOTIFICATION LETTER 通知信函

24 April 2025

Dear Registered Shareholders,

Hua Medicine (the "Company")

- Notice of publication of Annual Report 2024, Circular in relation to proposals for re-election of retiring directors, general mandates to repurchase and issue shares, reappointment of auditor, and notice of annual general meeting and Proxy Form (the "Current Corporate Communication")

The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.huamedicine.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corporate Communication and all future Corporate Communications (Note).

If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited ("Branch Share Registrar") at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mailing label (no stamp is needed if posted in Hong Kong) or by email to 2552-ecom@vistra.com. The Company will send the Current Corporate Communications to you in printed form free of charge upon your request.

It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the Branch Share Registrar at the abovementioned address by post or by email to 2552-ecom@vistra.com. If the Company does not have your functional email address, until such time that the functional email address is provided to the Branch Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications ("Notice of Publication") and Actionable Corporate Communications in electronic form. As such, the Company would only be able to send you the Notice of Publication and the Actionable Corporate Communications in printed form.

Should you have any queries relating to this notification, please call the Branch Share Registrar's telephone hotline at (852) 2980 1333 from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays).

Yours faithfully
Hua Medicine
Dr. Li Chen
Chief Executive Officer and
Executive Director

Note: Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; and (g) a proxy form.

Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.

各位登記股東:

華領醫藥 (「本公司」)

一年報2024、有關重選退任董事、回購及發行股份之一般授權及續聘核數師之建議及股東週年大會通告之通函及代表委任表格(「本次公司通訊」)之刊發通知

本公司的本次公司通訊之中、英文版本已分別上載於本公司網站(www.huamedicine.com)及香港聯合交易所有限公司(「聯交所」)之網站(www.hkexnews.hk)(「網站版本」)。 我們建議 閣下閱覽本公司本次及日後公司通訊(網註)的網站版本。

如 閣下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本及欲索取本次公司通訊及日後公司通訊的印刷本,請填妥及簽署隨附之回條,並以已預付郵費的郵奇標簽寄回本公司之香港股份過戶登記分處(「股份過戶登記分處」)卓佳證券登記有限公司(地址為香港夏懋道16號遠東金融中心17樓)(如在香港投寄毋須貼上郵票),或電郵至2552-ecom@vistra.com。本公司會因應 閣下之要求寄上公司通訊的印刷本,費用全免。

登記股東有責任提供有效的電子郵件地址。如 閣下尚未提供 閣下之電子郵件地址予本公司,或需更新 閣下之電子郵件地址,本公司建議 閣下填妥及簽署隨附之回條,並按上述地址以郵寄方式交回本公司的股份過戶登記分處或以電郵方式發送至2552-ecom@vistra.com。如果本公司沒有收到 閣下的有效電子郵件地址, 閣下將無法透過電子郵件方式收取以電子方式發送的公司通訊網站版本的登載通知(「登載通知」)及可供採取行動的公司通訊。本公司只能以印刷本方式向 閣下發送登載通知及可供採取行動的公司通訊之印刷本予 閣下,直至股份過戶登記分處收到 閣下有效的電子郵件地址為止。

倘 閣下對本通知有任何查詢,請於星期一至星期五 (公眾假期除外) 上午9時至下午6時,致電股份過戶登記分處熱線 (852) 2980 1333。

華領醫藥 行政總裁兼執行董事 陳力博士 ^誰
路

2025年4月24日

附註: 公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件,其中包括但不限於(a)董事會報告,公司年度帳目連同核數師報告以及(如適用)財務摘要報告;(b)中期報告及(如適用)中期摘要報告;(c)季度報告(如有);(d)會議通告;(e)上市文件;(f)通函;及(g)代表委任表格。

R	EPI	\mathbf{V}	FC	PM	回條
ĸ		/ W	T.) K VI	

Hua Medicine (the "Company") To: (Stock Code: 2552)

(Incorporated in the Cayman Islands with limited liability) c/o Tricor Investor Services Limited 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong

華領醫藥(「本公司」) (股份代號: 2552) (於開曼群島註冊成立的有限公司) 致: 經卓佳證券登記有限公司 香港夏慤道16號 遠東金融中心17樓

(Please use BLOCK LETTERS 請用正楷填寫)

Date:

日期

Part A 甲 部

I/We would like to receive the Current Corporate Communication and all future Corporate Communications and Actionable Corporate Communications in printed form in the manner indicated below: 本人/我們現欲以下列方式收取本次公司通訊及將來所有公司通訊及可供採取行動的公司通訊之印刷本:

"in ONLY ONE of the following boxes 請從下列選擇中,僅在其中一個空格內劃上「✓」號)

	I/We would like to receive a printed c本人/我們現欲收取一份英文印刷本	copy in the English language only; OR 本;或	
	I/We would like to receive a printed c本人/我們現欲收取一份中文印刷本	copy in the Chinese language only; OR 本;或	
	I/We would like to receive a printed c本人/我們現欲收取英文和中文各一	copy in both the English language and the Chinese language. 一份印刷本。	
Part Z	via the email address below:	iture Corporate Communications and Actionable Corporate Communications in ele 业電子郵件方式收取本公司所有將來的公司通訊及可供採取行動的公司通訊的登	
	(Please provide the email address in En (請以英文正楷填寫電郵地址)	nglish Capital Letters)	
Name(s) of Shareholder(s):		Signature:	
股東姓名	i i	(Please use BLOCK LETTERS 請用正楷填寫) 簽名:	
Address:			

聯絡電話號碼:

Contact telephone number:

ase complete and sign this form and return it by cutting and sticking the prepaid mailing label on an envelope to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited or via email to 2552-ecom@vistra

高光度主張同・化キス格計に同じは判確がする場所・22年。 Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts (seepler with a copy of the auditors' report and, where applicable, its summary interim report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; and (g) a proxy form.

公司總訊包括本公司營修成務干费修以採其任何證券得有人成投資大學參照成採取行動的任何文件,其中包括但不限於 (a) 董事會報告,公司年度帳目建同核數師報告以及 (如適用) 財務摘要報告; (b) 中期報告及 (如適用) 中期 摘奏報告; (c) 主义专政格官 如前: (d) 音樂館 (b) 上市文件; (1) 通道;(g) 代表委任表格。

Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders. 可供採取行動的公司通訊是指任何涉及要求股東指示其

Please cut the mailing label and stick it on an envelope to return this Reply Form to us.

No postage is necessary if posted in Hong Kong. 當 閣下寄回本回條時,請將郵寄標籤剪貼於信封上。 如在本港投寄, 閣下無需支付郵費或貼上郵票。



Mailing Label 郵寄標籤

Tricor Investor Services Limited 卓佳證券登記有限公司 Freepost No. 簡便回郵號碼: 10 GPO Hong Kong 香港